Cargando…
Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors
The COVID-19 pandemic caused by SARS-CoV-2 is unprecedented in recent memory owing to the non-stop escalation in number of infections and deaths in almost every country of the world. The lack of treatment options further worsens the scenario, thereby necessitating the exploration of already existing...
Autores principales: | Alanazi, Khalid Mashay, Farah, Mohammad Abul, Hor, Yan-Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781363/ https://www.ncbi.nlm.nih.gov/pubmed/35062685 http://dx.doi.org/10.3390/vaccines10010024 |
Ejemplares similares
-
Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme
por: Bahadur Gurung, Arun, et al.
Publicado: (2020) -
The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp
por: Gurung, Arun Bahadur, et al.
Publicado: (2021) -
Identification of SARS-CoV-2 inhibitors from extracts of Houttuynia cordata Thunb.
por: Bahadur Gurung, Arun, et al.
Publicado: (2021) -
In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020) -
Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)